Dr. Dvora Joseph Davey’s research focuses on how best to prevent and treat HIV and other sexually transmitted infections in peri-conception, pregnant women and couples. She has expertise in study design and use of epidemiological methods to inform interventions aimed at reducing the burden of HIV and related diseases on women, children, and families. Most recently, she is examining the combination of behavioral and biomedical approaches to HIV prevention among vulnerable populations. Dr. Joseph Davey is currently an Associate Professor (In Residence) in the Division of Infectious Diseases in the Geffen School of Medicine and in the Department of Epidemiology at the Fielding School of Public Health at UCLA. She is based in Cape Town, South Africa where she holds an Honorary Associate Professor Position at the University of Cape Town, South Africa School of Public Health’s Division of Epidemiology and Biostatistics. She is the PI of several NIH funded clinical trial and implementation science studies to evaluate how best to integrate PrEP and STI care into antenatal and postpartum care. She has been involved in research in Southern Africa since 2003 where she has developed and evaluated donor-funded epidemiological studies to inform effective, culturally relevant interventions aimed at reducing the burden of HIV and related diseases on women, children, and families. Prior to joining the faculty at UCLA, Dr. Joseph Davey was a Country Director and Technical Director for an NGO implementing HIV prevention and treatment programs in Mozambique. Dr. Joseph Davey completed her PhD in Epidemiology at UCLA and her MPH from Columbia University in Population and Family Health.

Contact: djosephdavey@mednet.ucla.edu

FEATURED PUBLICATIONS:

1. Joseph Davey DL, Mvududu R, Mashele N, Bheemraj K, Khadka N, Johnson LF, Dean SS, Gorbach P, Bekker LG, Coates TJ, Myer L. Initiation and continued use of oral pre-exposure prophylaxis among pregnant and postpartum women in South Africa (PrEP-PP): a demonstration cohort study. Lancet HIV. 2024 Nov;11(11):e746-e755. doi: 10.1016/S2352-3018(24)00240-6. PMID: 39477557.
https://pubmed.ncbi.nlm.nih.gov/39477557/ 

2. Joseph Davey DL, Bekker LG, Bukusi EA, Chi BH, Delany-Moretlwe S, Goga A, Lyerly AD, Mgodi NM, Mugo N, Myer L, Noguchi LM, Stranix-Chibanda L, Slack C, Pintye J. Where are the pregnant and breastfeeding women in new pre-exposure prophylaxis trials? The imperative to overcome the evidence gap. Lancet HIV. 2022 Mar;9(3):e214-e222. doi: 10.1016/S2352-3018(21)00280-0. Epub 2022 Jan 25. PMID: 35090604; PMCID: PMC9178651.
https://pubmed.ncbi.nlm.nih.gov/35090604/

3. de Voux A, Nyemba DC, Silliman M, Mashele N, Mvududu R, Myer L, Joseph Davey D. Point-of-care testing for sexually transmitted infections and HIV pre-exposure prophylaxis among pregnant women in South Africa, 2021-2022: randomised controlled trial. Sex Transm Infect. 2024 Feb 19;100(2):77-83. doi: 10.1136/sextrans-2023-055975. PMID: 38124133; PMCID: PMC11106734. https://pubmed.ncbi.nlm.nih.gov/38124133/

Last updated: 12/2/2024